Attached files
file | filename |
---|---|
8-K - FORM 8-K - UROPLASTY INC | c61719e8vk.htm |
Exhibit 99.1
UROPLASTY ANNOUNCES ADDITION OF ROBERT KILL
TO ITS BOARD OF DIRECTORS
TO ITS BOARD OF DIRECTORS
MINNEAPOLIS, MN, December 8, 2010 Uroplasty, Inc. (NASDAQ: UPI), a medical device company
that develops, manufactures and markets innovative proprietary products to treat voiding
dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors.
Mr. Kills appointment increases the membership on the Board to seven.
Mr. Kill (46) is the President, CEO and a Board member of Virtual Radiologic Corporation, a
Minneapolis-based, high growth provider of teleradiology and technology solutions to radiology
practices and hospitals throughout the United States. Prior to joining Virtual Radiologic, Mr.
Kill served as President of the Physicians Systems business at Misys Healthcare, a developer of
healthcare software systems. Earlier, he spent 10 years with Baxter Healthcare, where he held
senior leadership positions in operations, marketing and sales. He holds a B.A. in Economics from
the University of Notre Dame.
We are very pleased to have Rob join our Board at this key time at Uroplasty, said Patrick
Maxwell, Chairman of the Board. His 19 years of experience with growing medical products and
service companies will be extremely valuable to us as we execute our strategy to drive revenue
growth and enhance valuation for our shareholders.
I am excited to join Uroplastys Board as the Company re-launches its Urgent PC Neuromodulation
System in the U.S. for the treatment of overactive bladder, said Mr. Kill. I believe that my
experience in a high growth environment will be of value to Uroplastys Board and shareholders
during this pivotal time in the Companys development.
David Kaysen, President and CEO of Uroplasty said, Rob brought Virtual Radiologic public, growing
it several fold in four years, and then sold the company in a private transaction. As we roll out
the re-launch plans for Urgent PC, and prepare for our growth, Robs skills and expertise will be
invaluable in dealing with the challenges and opportunities ahead of us.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The
Netherlands and the United Kingdom, is a medical device company that develops,
manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.
Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only
FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based
treatment of overactive bladder and associated symptoms of urgency, frequency and urge
incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the
treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at
www.uroplasty.com.
Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding
future events and financial performance. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially from our anticipated results.
We discuss in detail the factors that may affect the achievement of our forward-looking statements
in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that the
rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that
other Medicare carriers or private payers will provide coverage for this treatment, or that any of
the other risks identified in our 10-K will not adversely affect our expectations as described in
these forward-looking statements.
For Further Information: |
||
Uroplasty, Inc.
|
EVC Group | |
David Kaysen, President and CEO, or
|
Doug Sherk/Jenifer Kirtland (Investors), | |
415.896.6820 | ||
Medi Jiwani, Vice President, CFO, Treasurer |
||
Chris Gale (Media), 646.201.5431 | ||
952.426.6140 |